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I
n this issue of Diabetes, two articles highlight the
emergence of inﬂammation’s contribution to insulin
resistance and to chronic diseases in humans. The
common feature in each article is the inﬂammation–
obesity–insulin resistance connection, but each article
approaches the investigation from a completely different
perspective. Speciﬁcally, the study of Ortega Martinez de
Victoria et al. (1) comments on factors related to macro-
phage activation in adipocytes as a source for cytokines
for systemic inﬂammatory effects. In contrast, the study of
Haus et al. (2) provides data on systemic effects resulting
from inﬂammatory activation, namely, the relationship of
cytokines with circulating lipid intermediates.
Approximately 2,000 years ago, Aulus (Aurelius) Corne-
lius Celsus, a Roman physician, was credited with the ﬁrst
recording of the cardinal signs of inﬂammation, which
included calor (warmth), dolor (pain), tumor (swelling),
and rubor (redness and hyperemia) (3). This general
description of inﬂammation appears to have served clini-
cal medicine well for most of the 2,000 years since it was
ﬁrst described. Until the recent past, no one would have
ever envisioned that inﬂammation would be considered a
root cause of the pathogenesis of metabolic abnormalities
associated with obesity or a potential molecular target for
diabetes therapies. But these statements for the inﬂamma-
tory pathway represent present-day reality for basic and
clinical human investigation.
The association of inﬂammation with carbohydrate me-
tabolism can actually be traced back to reports from the
1800s. Shoelson et al. (4) describe these reports in a
historical review. Speciﬁcally, they cite reports from over
a century ago in which high-dose salicylates appeared to
decrease glycosuria in individuals classiﬁed as diabetic
(presumably type 2 diabetes). The works of Ebstein in
1876 and Williamson in 1901 were also cited. These works
suggested remarkable beneﬁts of salicylates for treating
diabetes (4,5). In addition, clinical observations from the
1950s suggested that the use of high-dose aspirin in
individuals with diabetes resulted in marked improve-
ments in glycemia and, in at least one case, in the
discontinuation of insulin (4,6). The mechanism behind
these effects was not really identiﬁed because the focus on
investigation at that time was clearly on insulin secretion.
The current-day investigations that link obesity, inﬂam-
mation, and insulin resistance, including the articles fea-
tured in this issue of Diabetes, result from research
ﬁndings from the early 1990s. Research reported at the
time suggested that a protein called tumor necrosis fac-
tor-, produced by adipocytes and overproduced with
obesity, can attenuate metabolism locally and systemically
(4,7,8). Since those initial reports, research on adipocyte
secretions (e.g., interleukin-6, resistin, adiponectin, mono-
cyte chemoattractant protein-1, plasminogen activator in-
hibitor 1, and angiotensinogen) and their role in whole-
body insulin action has been aggressivley pursued. The
investigations have focused on intracellular pathways
modulated by these adipocyte products and have provided
a total restructuring of concepts about obesity, insulin
resistance, and development of type 2 diabetes. Speciﬁ-
cally, research has established that the link between
inﬂammation and insulin resistance resides at the level of
the IB kinase- (IKK)/NFkB axis (4,9). As such, modu-
lation of this system with regard to clinical treatment is
being actively investigated.
The precise physiological events leading to initiation of
the inﬂammatory response in obesity remain incompletely
understood. However, one emerging hypothesis, as re-
cently evaluated by Regazzetti et al. (10), envisions hyp-
oxia as a novel mechanism participating in insulin
resistance in adipose tissue of obese patients. It has been
suggested that hypertrophic adipocytes become hypoper-
fused, creating regional areas of microhypoxia leading to
increased expression of hypoxia-inducible factor-1. Acti-
vation of JNK1 and IKK/NFkB pathways along with in-
creased expressions of genes involved in inﬂammation and
endoplasmic reticulum stress appears to be enhanced in
hypoxic adipose tissue. This may lead to the release of
chemokines recruiting macrophages into the adipose tis-
sue and end with the formation of crown-like structures
and adipocyte death (11,12). Thus, microhypoxia is emerg-
ing as a mechanism suggested to exacerbate the proin-
ﬂammatory nature of adipose tissue (10–12).
It has been suggested that obese individuals are associ-
ated with a greater rate of fatty acid breakdown and
uptake compared with lean individuals, and this higher
ﬂux is postulated to be an important mediator of insulin
resistance (13). When fatty acids are taken up by periph-
eral tissues, they can undergo -oxidation in the mitochon-
dria or be stored as intramuscular triglycerides. When
there is increased fatty acid ﬂux in obesity and the
efﬁciency of skeletal muscle to dispose of fatty acids via
oxidation or storage is maximized, various fatty acid
“intermediates” (diacylglyerol, ceramide, etc.) accumulate
in skeletal muscle (13). Ectopic lipid accumulation is
postulated to impair insulin receptor signaling and to
contribute to insulin resistance (13–16). It is believed,
however, that the accumulation of intramuscular triglyc-
erides may not be the direct cause of insulin resistance but
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DIABETES, VOL. 58, FEBRUARY 2009 307is more an inert marker for the presence of other bioactive
lipid species (diacylglyerol, fatty acyl-coenzyme A, and
ceramides) that have been directly linked to defects in
insulin signaling (4,9,13–16). Speciﬁcally, there is evidence
to suggest that speciﬁc bioactive lipid species inside the
muscle cell can activate protein kinase C, which in turn
inhibits tyrosine phosphorylation of the insulin receptor
and the insulin receptor substrates. In addition, ceramides
activate speciﬁc protein phosphatases that dephosphory-
late Akt/protein kinase B, resulting in inhibition of GLUT4
translocation and glycogen synthesis. More recently, Wang
et al. (17) used skeletal muscle–speciﬁc lipoprotein lipase
knockout mice and evaluated the impact of reduced
lipoprotein delivery on insulin sensitivity. The data dem-
onstrated that lipoprotein lipase–derived lipids modulated
insulin signaling pathways, particularly basal and insulin-
stimulated Akt activation. Thus, it is very clear that
intramuscular lipid accumulation is detrimental to insulin
signaling, but the cause of this accumulation is less
evident.
The association of insulin resistance with lipid interme-
diates is not a novel idea; however, the novelty of the work
by Haus et al. (2) really revolves around the quantiﬁcation
and identiﬁcation of ceramide subspecies in the circula-
tion. The results demonstrate that plasma levels are ele-
vated in type 2 diabetes and that the lipid species appear
not only to be associated with the severity of insulin
resistance but also to be a marker of inﬂammation, i.e.,
tumor necrosis factor- levels. So, what is the next step for
this research? Are plasma ceramides now considered a
surrogate marker for tissue lipid stores? Would they be
valuable markers to assess the effectiveness of strategies
to reduce inﬂammation at the myocellular level? If so,
would they be viable markers that give us insight into
muscle metabolism and eliminate the need to obtain
muscle tissue by biopsy? Do plasma ceramides really serve
to identify individuals at high risk to develop type 2
diabetes as suggested? Given the observations in this
study, these are important questions that now need to be
answered.
The most relevant question, however, is whether thera-
pies that speciﬁcally target inﬂammation will evolve into
future diabetes medications. This very idea is being ac-
tively investigated as suggested for ongoing National Insti-
tutes of Health trials such as Targeting INﬂammation
Using SALsalate in Type 2 Diabetes (TINSAL-T2D) and
other proof-of-concept studies (18,19). With the focus now
clearly on modulating the inﬂammatory pathway as a
potential target for future diabetes therapies, it is truly an
exciting time for human investigation. However, let us not
forget that the interesting reports from the 1950s appear to
be the ﬁrst to suggest modulation of inﬂammation as a
therapy for diabetes. Given the lack of understanding of
insulin action during the 1950s, it is understood why
research into inﬂammation was not given more attention.
In this regard, the present-day approach of modulating
inﬂammation as a potential diabetes therapy reminds me
of the movie from the 1980s, in which Michael J. Fox goes
back in time and then returns to the present. In this regard,
we can appreciate that the focus on inﬂammation in regard
to diabetes is truly an area that is going “Back to the
Future.”
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